Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022 - new market research report

London 8/28/2012 05:30 AM GMT (TransWorldNews)

Gammagard Liquid (Alzheimer's disease) – Analysis and Forecasts to 2022. The pharmaceuticals report, "Gammagard Liquid (Alzheimer's disease) – Analysis and Forecasts to 2022" provides Gammagard Liquid global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.


- Therapy area profile including patient population for the US and EU5 (six major markets)
- Analysis and review of Gammagard Liquid including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Gammagard Liquid including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2014-2022 for Gammagard Liquid

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets


Gammagard Liquid, Kiovig, Immune Globulin Intravenous (Human) 10%, Baxter, Alzheimer's disease, dementia

Click for Report details:Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022


News Alerts

Receive alerts for to your inbox. Sign up for News Alerts